Ophthalmic Bevacizumab Sponsor Not Giving Up On EMA Rejection

 
• By Neena Brizmohun

The European Medicines Agency has been asked to re-examine its rejection of the EU marketing application for Ipique, which, if approved, could become the first drug containing bevacizumab to be authorized for use in neovascular (wet) macular degeneration.

Share close up view of human eye with data illustration, robotic concept
Ipique is an investigational ophthalmic formulation of bevacizumab • Source: Alamy

More from Europe

More from Geography